Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells $689,760.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $86.22, for a total value of $689,760.00. Following the transaction, the chief operating officer now owns 205,695 shares of the company’s stock, valued at $17,735,022.90. This trade represents a 3.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jim Wassil also recently made the following trade(s):

• On Thursday, January 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00.
• On Monday, December 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $92.49, for a total transaction of $739,920.00.

Vaxcyte Trading Up 2.0 %

Shares of NASDAQ:PCVX traded up $1.70 on Tuesday, hitting $86.51. 1,752,866 shares of the company were exchanged, compared to its average volume of 1,227,603. The firm has a market capitalization of $10.78 billion, a P/E ratio of -18.81 and a beta of 0.98. The stock’s 50 day moving average price is $87.46 and its 200 day moving average price is $94.42. Vaxcyte, Inc. has a 1-year low of $58.10 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same quarter in the previous year, the business earned ($0.91) earnings per share. On average, equities analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Vaxcyte

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. boosted its position in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after acquiring an additional 93 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Vaxcyte by 5.2% during the third quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company’s stock worth $252,000 after buying an additional 110 shares during the period. CIBC Asset Management Inc lifted its position in shares of Vaxcyte by 3.6% during the 3rd quarter. CIBC Asset Management Inc now owns 3,136 shares of the company’s stock worth $358,000 after purchasing an additional 110 shares during the last quarter. Riverview Trust Co purchased a new position in Vaxcyte in the third quarter valued at approximately $27,000. Finally, Amalgamated Bank raised its stake in Vaxcyte by 8.6% during the 3rd quarter. Amalgamated Bank now owns 4,081 shares of the company’s stock worth $466,000 after acquiring an additional 322 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on PCVX shares. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research report on Friday, December 20th. They issued a “buy” rating and a $135.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte presently has an average rating of “Buy” and an average price target of $145.71.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.